Steven Keith  Burke net worth and biography

Steven Burke Biography and Net Worth

Steven K. Burke, M.D. joined Akebia in August 2019 and is Senior Vice President, Research & Development and Chief Medical Officer. Prior to joining Akebia, he served as Senior Vice President and Chief Medical Officer of Proteon Therapeutics, Inc., a company developing therapeutics focused on patients with kidney and vascular diseases, from 2006 to 2019. From 2000 to 2006, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs at Genzyme Corporation, where he worked from 2001 to 2006. From 1994 to 2001, Dr. Burke held roles at GelTex Pharmaceuticals, Inc., including Vice President of Clinical Research and Medical Director, and before that he held positions at Glaxo, Inc. Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical College. He completed a medical residency and fellowship at Brigham and Women’s Hospital and is certified by the American Board of Internal Medicine.

What is Steven Keith Burke's net worth?

The estimated net worth of Steven Keith Burke is at least $1.33 million as of February 1st, 2024. Dr. Burke owns 711,376 shares of Akebia Therapeutics stock worth more than $1,330,273 as of December 18th. This net worth approximation does not reflect any other assets that Dr. Burke may own. Additionally, Dr. Burke receives an annual salary of $937,390.00 as SVP at Akebia Therapeutics. Learn More about Steven Keith Burke's net worth.

How old is Steven Keith Burke?

Dr. Burke is currently 63 years old. There are 3 older executives and no younger executives at Akebia Therapeutics. Learn More on Steven Keith Burke's age.

What is Steven Keith Burke's salary?

As the SVP of Akebia Therapeutics, Inc., Dr. Burke earns $937,390.00 per year. The highest earning executive at Akebia Therapeutics is Mr. John P. Butler MBA, CEO, President & Director, who commands a salary of $1,810,000.00 per year. Learn More on Steven Keith Burke's salary.

How do I contact Steven Keith Burke?

The corporate mailing address for Dr. Burke and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Steven Keith Burke's contact information.

Has Steven Keith Burke been buying or selling shares of Akebia Therapeutics?

Steven Keith Burke has not been actively trading shares of Akebia Therapeutics during the past quarter. Most recently, Steven Keith Burke sold 24,311 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $1.68, for a transaction totalling $40,842.48. Following the completion of the sale, the senior vice president now directly owns 711,376 shares of the company's stock, valued at $1,195,111.68. Learn More on Steven Keith Burke's trading history.

Who are Akebia Therapeutics' active insiders?

Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.

Are insiders buying or selling shares of Akebia Therapeutics?

During the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 187,893 shares worth more than $300,597.66. The most recent insider tranaction occured on February, 29th when COO Michel Dahan sold 8,661 shares worth more than $13,684.38. Insiders at Akebia Therapeutics own 4.1% of the company. Learn More about insider trades at Akebia Therapeutics.

Information on this page was last updated on 2/29/2024.

Steven Keith Burke Insider Trading History at Akebia Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2024Sell24,311$1.68$40,842.48711,376View SEC Filing Icon  
5/16/2023Sell63,567$1.07$68,016.69530,487View SEC Filing Icon  
2/28/2022Sell7,400$2.15$15,910.00View SEC Filing Icon  
4/1/2021Sell1,081$3.40$3,675.40
11/20/2019Buy27,000$3.58$96,660.0037,000View SEC Filing Icon  
See Full Table

Steven Keith Burke Buying and Selling Activity at Akebia Therapeutics

This chart shows Steven Keith Burke's buying and selling at Akebia Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akebia Therapeutics Company Overview

Akebia Therapeutics logo
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.88
Low: $1.86
High: $1.90

50 Day Range

MA: $1.77
Low: $1.28
High: $2.13

2 Week Range

Now: $1.88
Low: $0.80
High: $2.48

Volume

614,034 shs

Average Volume

3,008,998 shs

Market Capitalization

$409.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7